What are the risks of using Depo Provera (medroxyprogesterone acetate) for more than 2 years?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Risks of Long-Term Depo Provera Use Beyond 2 Years

Despite the FDA's black box warning about bone mineral density loss, the American College of Obstetricians and Gynecologists (ACOG) does not advise limiting Depo Provera use to 2 years or routinely monitoring bone density after this timeframe, as the benefits of preventing unwanted pregnancy generally outweigh the risks of bone density loss. 1

Bone Health Concerns

  • Depo Provera causes reductions in bone mineral density (BMD), which prompted the FDA to issue a black box warning in 2004 1
  • Subsequent research has shown substantial recovery of BMD after discontinuation of Depo Provera 1
  • The risk of decreased BMD increases with longer duration of use, particularly beyond 2 years 2
  • Despite these concerns, ACOG does not recommend limiting use to 2 years due to the risk of unwanted pregnancy if contraceptive options are limited 1

Menstrual Changes

  • Nearly all patients experience menstrual irregularities initially, which typically improve over time 1
  • With continued use beyond 2 years, amenorrhea becomes increasingly common, reported by 57% of women after one year of treatment 3
  • These menstrual changes are generally not harmful but may affect patient satisfaction and continuation rates 1

Weight Gain

  • Weight gain is a common side effect with long-term use 1
  • Studies in both adolescents and adults suggest that weight gain status at 6 months is a strong predictor of future excessive weight gain with ongoing DMPA use 1
  • Not all patients experience weight gain, but those who show early weight gain (>5% at 6 months) may experience significant increases in BMI with continued use 1

Return to Fertility

  • Long-term DMPA use is associated with a delayed return to fertility, typically 9 to 18 months after discontinuation 1
  • This delay occurs while the endometrial lining returns to its pre-DMPA state and ovulatory function returns 1
  • Both subcutaneous and intramuscular DMPA formulations show similar delays to fertility after injection 1

Other Potential Side Effects

  • Headache, mastalgia (breast pain), hair loss, and changes in libido may occur with continued use 1
  • Long-term studies have shown no increased risk for ovarian, liver, or cervical cancer 3
  • DMPA may actually reduce the risk of endometrial cancer with extended use 3

Recommendations for Patients Using Depo Provera Long-Term

  • All patients using DMPA beyond 2 years should be counseled about measures to promote skeletal health 1:
    • Daily intake of 1300 mg of calcium and 600 IU of vitamin D
    • Regular weight-bearing exercise
    • Smoking cessation
  • Patients should be evaluated for other risk factors for osteoporosis when considering long-term use 1
  • Annual healthcare visits are recommended for blood pressure checks and other healthcare needs during treatment 2

Clinical Considerations

  • For patients with risk factors for osteoporosis (family history, chronic alcohol or tobacco use, eating disorders, or illness requiring chronic corticosteroid use), alternatives to DMPA may be preferable for long-term contraception 1
  • The convenience of DMPA (injections every 13 weeks) makes it an attractive option for many patients who have difficulty with daily, weekly, or monthly contraceptive methods 1
  • Counseling about potential side effects before initiation improves continuation rates 1

Despite the concerns about bone health, the evidence suggests that for most women, the benefits of Depo Provera as an effective contraceptive method outweigh the risks, even with use beyond 2 years. However, individual risk factors should be considered, and bone health measures should be encouraged for all long-term users.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

3-month contraceptive injection approved.

FDA medical bulletin : important information for health professionals from the U.S. Food & Drug Administration, 1993

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.